3- [2- [4-(4-Fluorobenzoyl)piperidin- 1-yl]ethyl] -5,6,7,8-tetrahydro-4(3H)-quinazolinones: serotonin 5-HT2A receptor antagonists endowed with potent central action
- 31 August 1997
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 32 (7-8) , 651-659
- https://doi.org/10.1016/s0223-5234(97)83291-6
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Ketanserin Analogs: The Effect of Structural Modification on 5-HT2 Serotonin Receptor BindingJournal of Medicinal Chemistry, 1995
- Failure of the 5-HT2 receptor antagonist, ritanserin, to alter preference for alcohol in drinking ratsPharmacology Biochemistry and Behavior, 1993
- Naphthosultam derivatives: a new class of potent and selective 5-HT2 antagonistsJournal of Medicinal Chemistry, 1991
- Differential effects of a 5-HT2 receptor blocker on alcohol intake in rats selectively bred for high and low catecholamine responses to stressIntegrative Psychological and Behavioral Science, 1991
- 5‐HT2 receptor antagonism in dysthymic disorder: a double‐blind placebo‐controlled study with ritanserinActa Psychiatrica Scandinavica, 1991
- KetanserinDrugs, 1990
- Problems in in vitro receptor binding studies and identification and role of serotonin receptor sitesNeuropharmacology, 1984
- Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptorsLife Sciences, 1981
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Derivatives of Pyrimidol-4 and Quinazolinol-4Journal of the American Chemical Society, 1952